Welcome!

News Feed Item

Trichotillomania Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

Trichotillomania Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trichotillomania Global Clinical Trials Review, H2, 2014" provides data on the Trichotillomania clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trichotillomania. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trichotillomania. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Trichotillomania 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in North America 8
Top Countries Contributing to Clinical Trials in Middle East and Africa 9
Top Countries Contributing to Clinical Trials in Central and South America 10
Clinical Trials by G7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Drugs 21
Clinical Trial Overview of Top Institutes / Government 22
National Institute of Mental Health 22
Clinical Trial Overview of National Institute of Mental Health 22
Massachusetts General Hospital 23
Clinical Trial Overview of Massachusetts General Hospital 23
University of Chicago 24
Clinical Trial Overview of University of Chicago 24
American University of Beirut Medical Center 25
Clinical Trial Overview of American University of Beirut Medical Center 25
Yale University 26
Clinical Trial Overview of Yale University 26
University of South Florida 27
Clinical Trial Overview of University of South Florida 27
University of Sao Paulo 28
Clinical Trial Overview of University of Sao Paulo 28
Hamilton Health Sciences 29
Clinical Trial Overview of Hamilton Health Sciences 29
University of Pennsylvania 30
Clinical Trial Overview of University of Pennsylvania 30
Stanford University 31
Clinical Trial Overview of Stanford University 31
Five Key Clinical Profiles 32
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 51

List of Tables
Trichotillomania Therapeutics, Global, Clinical Trials by Region, 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries, 2014* 8
Trichotillomania Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 9
Trichotillomania Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 10
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 20
Trichotillomania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 22
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 23
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2014* 24
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by American University of Beirut Medical Center, 2014* 25
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 26
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of South Florida, 2014* 27
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 28
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 29
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 30
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 31

List of Figures
Trichotillomania Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 8
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 20
GlobalData Methodology 50


Read the full report:
Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Analytic. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.